Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-04-22
2009-12-08
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S093200, C424S093600, C424S199100, C424S232100, C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
07628980
ABSTRACT:
The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.
REFERENCES:
patent: 3914408 (1975-10-01), Mebus
patent: 4191745 (1980-03-01), Mayr et al.
patent: 5338683 (1994-08-01), Paoletti
patent: 5403582 (1995-04-01), Nazerian et al.
patent: 5405772 (1995-04-01), Ponting
patent: 5753489 (1998-05-01), Kistner et al.
patent: 5756341 (1998-05-01), Kistner et al.
patent: 6190655 (2001-02-01), Lyman et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6685950 (2004-02-01), Weber et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6805870 (2004-10-01), Mayr
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 6976752 (2005-12-01), Parish et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2370573 (2002-07-01), None
patent: 90/12882 (1990-11-01), None
patent: 95/22978 (1995-08-01), None
patent: WO 95/22978 (1995-08-01), None
patent: WO 97/02355 (1997-01-01), None
patent: WO 97/31119 (1997-08-01), None
patent: 98/17283 (1998-04-01), None
patent: WO 99/07869 (1999-02-01), None
patent: WO 00/29428 (2000-05-01), None
patent: 01/68820 (2001-09-01), None
patent: WO 01/68820 (2001-09-01), None
patent: WO 01/89559 (2001-11-01), None
patent: 02/42480 (2002-05-01), None
patent: WO 02/42480 (2002-05-01), None
Musch, et al. Phase II clinical trial of combined natural interferon-beta plus recombinat interferon-gamma treatment of chronic hpatitis B. Hepatogastroenterology. 1998; 45(24):2282-94.
Sayers, et al. Antitumor Effects of alpha-interferon and gamma-Interferon on a Murine Renal Cancer (Renca) in Vitro and in Vivo. Cancer Research. 1990; 50: 5414-5420.
Wyatt, et al. Priming and boosting immunity to tespiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine. 1999;18(5-6):392-397.
Maraskovsky, et al. Dramatic Increase in the Numbers of Functionally Mature Dendritic Cels in Flt2 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified. J Exp Med. 1996; 184:1953-1962.
Mayr, et al. The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccine and Behavior in Organisms with a Debilitated Defence Mechansim. Zbl. Bakt. Hyg., I. Abt. Orig. B. 1978;167:375-390.
Antoine, et al. The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses. Virology 1998; 244:365-396.
Stickl, et al. Dtsch. Med. Wochenschr. 1974; 99:2386-2392.
Marchant and Goldman. T cell-mediated immune responses in human newborns: ready to learn? Clinical and Experimental Immunology. Clinical and Experimental Immunology. 2005; 141: 10-18.
Goerner, et al., Expansion and Transduction of Nonenriched Human Cord Blood Cells Using HS-5 Conditioned Medium and FLT3-L. Journal of Hematotherapy & Stem Cell Research 9:759-765 (2000).
Murphy, et al. Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants. MMWR. 2008; 57 (04);1-47,51.
Recommendation of the Immunization Practices Advisory Committee (ACIP) Diphtheria, Tetanus, and Pertussis: Guidelines for Vaccine Prophylaxis and Other Preventive Measures. MMWR. 1985; 34(27);405-14,419-26.
Lee, WM. Hepatitis B Virus Infection. NEJM. 1997; 337(24): 1733-45.
Gringeri, et al. Anti-Alpha-Interferon (IFN-Alpha) Immunization—A 2-Year Follow-Up of 44 HIV-Infected Patients. Aids Research and Human Retroviruses, 1995 , V 11 , S1 , p. S168.
Tanaka, et al. Immunotherapy of a Vaccinia Colon Oncolysate Prepared With Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon-Alpha Increases the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma. J. Immunother. 1994; 16(4):, 283-293.
Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003. vol. 112 No. 6, p. 1442-1446.
Goerner, et al. Expansion and Transduction of Nonenriched Human Cord Blood Cells Using HS-5 Conditioned Medium and FLT3-L. Journal of Hematotherapy & Stem Cell Research. 2000; 9:759-765.
Maraskovsky, et al. Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified. j. Exp. Med. 1996;184:1953-1962.
U.S. International Trade Commission, Inv. No. 337-TA-550, Order No. 10: Denying Respondent's Motion to Terminate and Entry of Consent Order, Nov. 30, 2005, pp. 1-8.
Inv. No. 337-TA-550, Complainant Bavarian Nordic's Motion for Summary Determination of Infringement of the '893 Patent, Mar. 20, 2005, pp. 1-15.
U.S. International Trade Commission, Inv. No. 337-TA-550, Complainant's Petition for Review of the Final Initial Determination, Sep. 18, 2006, pp. 1-52.
U.S. International Trade Commission, Inv. No. 337-TA-550, Order No. 16: Granting Complainant's Motion to Declassify Confidential Information, Feb. 15, 2006, pp. 1-8.
U.S. International Trade Commission, Inv. No. 337-TA-550, Bavarian Nordic's Complaint Under Section 337 of the Tariff Act of 1930, Aug. 19, 2005, pp. 1-30.
Federal Register, vol. 70, No. 184, Sep. 23, 2005, pp. 55918-55919.
U.S. International Trade Commission, Inv. No. 337-TA-550, Memorandum in Opposition to Respondent's Motion to Terminate, Nov. 28, 2005, pp. 1-17.
U.S. International Trade Commission, Inv. No. 337-TA-550, Memorandum in Support of Respondent's Motion for Summary Determination, Mar. 30, 2005, pp. 1-48.
U.S. International Trade Commission, Inv. No. 337-TA-550, Appendix to Memorandum in Support of Respondent's Motion for Summary Determination, vol. 1 of 3, Oct. 31, 2005, pp. 1-64.
U.S. International Trade Commission, Inv. No. 337-TA-550, Appendix to Memorandum in Support of Respondent's Motion for Summary Determination, vol. 2 of 3, Dec. 1, 2005, pp. 1-45.
U.S. International Trade Commission, Inv. No. 337-TA-550, Appendix to Memorandum in Support of Respondent's Motion for Summary Determination, vol. 3 of 3.
U.S. International Trade Commission, Inv. No. 337-TA-550, Supplemental Appendix.
U.S. International Trade Commission, Inv. No. 337-TA-550, Notice of Investigation, Sep. 19, 2005.
U.S. International Trade Commission, Inv. No. 337-TA-550, Respondent's Opposition to Complainant's Motion to Declassify Confidential Information, Feb. 13, 2006, pp. 1-9.
U.S. International Trade Commission, Inv. No. 337-TA-550, Motion for Leave to File Reply in Support of Respondent's Motion for Summary Determination (pp. 1-2), Respondent's Certification Pursuant to Ground Rule 3.2 (p. 1), and Reply in Support of Respondent's Motion for Summary Determination, Apr. 5, 2005 (pp. 1-3), Apr. 5, 2006.
U.S. International Trade Commission, Inv. No. 337-TA-550, Respondent's Notice of Prior Art, Feb. 3, 2006, pp. 1-8.
U.S. International Trade Commission, Inv. No. 337-TA-550, Response of Acambis plc Under Section 337 of the Tariff Act of 1930 and Notice of Investigation, Oct. 21, 2005, pp. 1-24.
U.S. International Trade Commission, Inv. No. 337-TA-550, Commission Investigative Staff's Response to the Private Parties' Motions in Limine, May 3, 2006, pp. 1-5.
U.S. International Trade Commission, Inv. No. 337-TA-550, Commission Investigative Staff's Notice of Prior Art, Feb. 3, 2006.
U.S. International Trade Commission, Inv. No. 337-TA-550, Consent Order Stipulation, Nov. 2, 2005, pp. 1-4.
U.S. International Trade Commission, Inv. No. 337-TA-550, Consent Order Stipulation (pp. 1-4) with Commission Opinion
Chaplin Paul
Suter Mark
Vollstedt Sabine
Bavarian Nordic A/S
Law Office of Salvatore Arrigo
Mosher Mary E
Snyder Stuart W
LandOfFree
Modified vaccinia virus ankara for the vaccination of neonates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia virus ankara for the vaccination of neonates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia virus ankara for the vaccination of neonates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074653